Panacea Announces Collaboration With MIT

Panacea Pharmaceuticals, Inc. has signed a Collaborative Research Agreement with researchers at the Massachusetts Institute of Technology (MIT) in Cambridge, Massachusetts covering the development of all-human, ultra-affinity, single-chain antibodies for its cancer platform technology. The research group is led by K. Dane Wittrup, Ph.D., J.R. Mares Professor of Chemical Engineering and Bioengineering at MIT. Dr. Read more about Panacea Announces Collaboration With MIT[…]

Proteome And Celera Genomics Announce Collaboration

Proteome, Inc., has announced a key strategic collaboration for advancing biology with Celera Genomics, a PE Corporation business. Proteome’s BioKnowledge Library, which includes human, worm and yeast annotation, will be linked and distributed through the Celera Discovery System. This linkage between the two databases is expected to provide researchers with a novel tool for understanding Read more about Proteome And Celera Genomics Announce Collaboration[…]

Sangamo And Procter & Gamble Sign Collaborative Research Agreement

Sangamo BioSciences, Inc. has signed a collaborative research agreement with Procter & Gamble Pharmaceuticals. Under the terms of the agreement, Sangamo will provide specific Universal GeneTools to P&G Pharmaceuticals for use in their internal research and validation programs. Financial terms were not disclosed. “Sangamo is pleased to provide P&G Pharmaceuticals with our engineered transcription factors Read more about Sangamo And Procter & Gamble Sign Collaborative Research Agreement[…]

Ligand And Lilly Advance Novel Drugs

Ligand Pharmaceuticals Incorporated has announced that LY510929, a novel PPAR agonist, and a back-up compound have been declared clinical candidates for development as novel oral treatments for type 2 diabetes and cardiovascular disease. Ligand expects an Investigational New Drug Application (IND) to be filed with the FDA for LY510929 or the back-up compound in the Read more about Ligand And Lilly Advance Novel Drugs[…]

Dow To Acquire Collaborative BioAlliance

The Dow Chemical Company has signed a definitive agreement to purchase The Collaborative Group’s Biotechnology Services Division, including all of the assets of Collaborative BioAlliance, Inc. (CBA) and Collaborative Smithfield Corp. Pending regulatory review and obtaining certain third-party consents, the acquisition is expected to close towards the end of November. The financial terms of the Read more about Dow To Acquire Collaborative BioAlliance[…]

Cetek And Taisho Sign Multi-Target Screening Agreement

Cetek Corporation has announced a screening agreement with Taisho Pharmaceutical Co., Ltd. utilizing Cetek’s proprietary technology in screening Taisho’s targets. Under the agreement, Cetek will develop assays for Taisho’s targets and screen against libraries from Taisho. “We are pleased to gain access to Cetek’s screening technology and have it contribute to our drug discovery efforts,” Read more about Cetek And Taisho Sign Multi-Target Screening Agreement[…]

Axys Announces Screening Agreement With Bristol-Myers Squibb

Axys Pharmaceuticals, Inc. announced that Axys Advanced Technologies, Inc. (AAT), its combinatorial chemistry subsidiary, entered into an agreement with Bristol-Myers Squibb Company (BMS) to provide them with diverse compounds for pharmaceutical screening. Axys will also provide BMS with enabling technologies for reproducing and expanding the library chemistries. This agreement provides for payments to AAT for Read more about Axys Announces Screening Agreement With Bristol-Myers Squibb[…]

FDA Grants Fast Track Designation For Secretin

Repligen Corporation announced that the U.S. FDA has granted Fast Track designation for secretin for the treatment of pediatric autism. “We are very pleased that the FDA has designated this program for Fast Track status,” stated Walter C. Herlihy, President and CEO of Repligen Corporation. “We believe that this action affirms a heightened awareness to Read more about FDA Grants Fast Track Designation For Secretin[…]